GLP-1/GIP 30 mg

GLP-1/GIP – Dual Incretin Agonist for Metabolic Research

GLP-1/GIP receptor agonists are studied for their combined incretin pathway activation, with research focusing on metabolic regulation, energy balance, and nutrient signaling.

Key Research Areas:

• Metabolic Enhancement – The GLP-1/GIP dual agonist has been studied for its influence on metabolic regulation, with research exploring effects on energy balance in experimental models.

• Glucose Pathway Research – By mimicking incretin activity, this compound is investigated in studies examining glucose regulation and related metabolic processes.

• Appetite Management Potential – Research indicates that GLP-1/GIP agonists may affect satiety signaling, providing insights into appetite regulation in metabolic models.

• Lipid Metabolism Exploration – GLP-1/GIP has been evaluated in research for its potential influence on fat metabolism, making it of interest for studies involving lipid storage and utilization.

Chemical Name: GLP-1/GIP 30mg
Chemical Formula: C225H348N48068
Molecular Mass: 4813.53 g·mol⁻¹
Total Amount of Active Ingredient: 36.35mg
Appearance: Lyophilized peptide powder
Shelf Life: 36 months (about 3 years)
Verified Purity: 99.015% (COA #22339)
View Verified Certificate of Analysis

Most Common Side Effects of GLP-1/GIP Dual Agonists

• Nausea: A queasy sensation in the stomach, often occurring when initiating treatment.
  

• Vomiting: Forceful expulsion of stomach contents, sometimes accompanying nausea.
  Diarrhea: Frequent loose or watery stools, typically temporary as the body adjusts,
  

• Constipation: Difficulty passing stools, leading to discomfort or bloating.
  

• Decreased Appetite: Reduced hunger, which can aid in weight management.